TIMCC

Tumor Infiltrating Myeloid Cell Compartment

Coordinatore	ACADEMISCH ZIEKENHUIS LEIDEN    more  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Mr. Nome: Ruud Cognome: Esveld Email: send email Telefono: +31 71 526 9566 Fax: +31 71 526 8275
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	3˙756˙469 €
EC contributo	3˙756˙469 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-ITN
Funding Scheme	MC-ITN
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-11-01   -   2016-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ACADEMISCH ZIEKENHUIS LEIDEN  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Mr. Nome: Ruud Cognome: Esveld Email: send email Telefono: +31 71 526 9566 Fax: +31 71 526 8275	NL (LEIDEN)	coordinator	870˙434.20
2	QUEEN MARY UNIVERSITY OF LONDON  Organization address address: 327 MILE END ROAD city: LONDON postcode: E1 4NS contact info Titolo: Dr. Nome: Thorsten Cognome: Hagemann Email: send email Telefono: +44 20 7882 3590 Fax: +44 20 7882 3885	UK (LONDON)	participant	573˙413.25
3	UPPSALA UNIVERSITET  Organization address address: SANKT OLOFSGATAN 10 B city: UPPSALA postcode: 751 05 contact info Titolo: Mrs. Nome: Pirkko Cognome: Boox Email: send email Telefono: +46 18 4714815 Fax: +46 18 4715077	SE (UPPSALA)	participant	523˙150.30
4	STICHTING HET NEDERLANDS KANKER INSTITUUT  Organization address address: PLESMANLAAN 121 city: AMSTERDAM postcode: 1066 CX contact info Titolo: Dr. Nome: Henri Cognome: Van Luenen Email: send email Telefono: 31205122097	NL (AMSTERDAM)	participant	477˙022.90
5	RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN  Organization address address: REGINA PACIS WEG 3 city: BONN postcode: 53113 contact info Titolo: Ms. Nome: Daniela Cognome: Hasenpusch Email: send email Telefono: +49 228 737 274 Fax: +49 228 736 479	DE (BONN)	participant	447˙437.75
6	TECHNISCHE UNIVERSITAET DRESDEN  Organization address address: HELMHOLTZSTRASSE 10 city: DRESDEN postcode: 1069 contact info Titolo: Mrs. Nome: Beate Cognome: Brenner Email: send email Telefono: +49 351 463 421 85 Fax: +49 351 463 397 42	DE (DRESDEN)	participant	447˙437.75
7	ALLIGATOR BIOSCIENCE AB  Organization address address: SCHEELEVAGEN 19A city: LUND postcode: 22370 contact info Titolo: Mrs. Nome: Jennifer Cognome: Glennon Email: send email Telefono: +46 723 044 524 Fax: +46 462 864 290	SE (LUND)	participant	226˙772.05
8	SYNOVO GMBH  Organization address address: Paul Ehrlich Str 15 city: TUEBINGEN postcode: 72076 contact info Titolo: Dr. Nome: Michael Cognome: Burnet Email: send email Telefono: 497072000000 Fax: 497072000000	DE (TUEBINGEN)	participant	190˙800.72

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The ITN TIMCC brings together eight expert teams from different disciplines within Immunology, Genetics and Oncology, to provide substantive and methodological training in the analysis of the role of the Tumor Infiltrating Myeloid Cell Compartment (TIMCC) of the innate immune system. Leukocytes recruited to (pre)malignant tissues are mainly myeloid cells. They can either prevent or functionally contribute to cancer development. However, the mechanisms underlying pro- versus anti-tumor programming of neoplastic tissues by these immune cells remain obscure. The ITN TIMCC aims to improve anti-tumor therapy by defining general and tumor type specific molecular and cellular immunological pathways (e.g signal transduction and downstream effector pathways) in tumor development and during therapeutic intervention based on an extensive analysis of the infiltrating myeloid cell compartment in human tumor biopsies using a large variety of techniques and functional analysis of the corresponding models of a variety of human tumors, affecting different organs, in a unique cohort of genetically modified mice treated with different types of anti-tumor therapy. The program will train the appointed researchers in a variety of methodology and technology from genomic technologies and bioinformatics via genetically modified mice to the design and application of therapeutic strategies to understand and manipulate the many interactions of the myeloid cell compartment with developing tumors. By defining underlying molecular and cellular pathways new targets will be identified to be explored by the participating SMEs. The program will deliver young researchers equipped with a broad knowledge in immunology, genetics and oncology and insight in the complexity of translational medicine therefore better prepared to meet new challenges in the field.'